Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2016

01-07-2016 | Original Article

Soluble Dietary Fiber Can Protect the Gastrointestinal Mucosa Against Nonsteroidal Anti-Inflammatory Drugs in Mice

Authors: Hiroshi Satoh, Tetsuro Urushidani

Published in: Digestive Diseases and Sciences | Issue 7/2016

Login to get access

Abstract

Background

Nonsteroidal anti-inflammatory drug (NSAID)-induced small intestinal damage is a serious problem in patients, but effective therapy is not available at present.

Aims

The effects of feeding conditions and dietary fiber (DF) on NSAID-induced gastrointestinal lesions were examined in mice.

Methods

NSAIDs (indomethacin, diclofenac, loxoprofen, aspirin) were administered to male mice in various feeding conditions. Gastrointestinal lesions were examined 24 h after NSAID dosing. Regular diets, dietary-fiber-free diet (FFD), and diets supplemented with various types of DF were given to mice.

Results

NSAIDs produced marked ulcers and perforations selectively in the gastric antrum when they were administered after feeding of regular diet for 2 h after a 22-h fast. When NSAIDs, except for aspirin, were administered in unfasted conditions, they caused marked lesions in the small intestine. When mice were given FFD, antral ulcers and intestinal lesions induced by indomethacin (30 mg/kg, s.c.) markedly decreased, but when cellulose, an insoluble DF, was added to FFD, the lesions appeared again. The addition of pectin, a soluble DF, to regular diet containing 4.1 % crude fiber significantly inhibited the formation of antral ulcers as well as intestinal lesions caused by indomethacin or diclofenac (100 mg/kg, s.c.).

Conclusions

The results indicated that NSAIDs given after feeding of diet produced ulcers selectively in the gastric antrum. The severity of the gastrointestinal lesions depended on the concentration of soluble or insoluble DF in food. Our results suggest that soluble DF such as pectin may be a safe means for protecting the gastrointestinal mucosa against NSAIDs.
Literature
1.
go back to reference Graham DY, Opekum AR, Willingham FF, et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–59.CrossRefPubMed Graham DY, Opekum AR, Willingham FF, et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–59.CrossRefPubMed
2.
go back to reference Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172–1178.CrossRefPubMed Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172–1178.CrossRefPubMed
3.
go back to reference Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroent Hepatol. 2005;3:133–141.CrossRef Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroent Hepatol. 2005;3:133–141.CrossRef
4.
go back to reference Matsumoto T, Kudo T, Esaki M, et al. Prevalence of nonsteroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol. 2008;43:490–496.CrossRefPubMed Matsumoto T, Kudo T, Esaki M, et al. Prevalence of nonsteroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol. 2008;43:490–496.CrossRefPubMed
5.
go back to reference Leung WK, Bjarnason I, Wong VW, et al. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet. 2007;369:614.CrossRefPubMed Leung WK, Bjarnason I, Wong VW, et al. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet. 2007;369:614.CrossRefPubMed
6.
go back to reference Shiotani A. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol. 2008;43:581–588.CrossRefPubMed Shiotani A. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol. 2008;43:581–588.CrossRefPubMed
7.
go back to reference Endo H, Hosono K, Inamori M, et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol. 2009;44:544–549.CrossRefPubMed Endo H, Hosono K, Inamori M, et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol. 2009;44:544–549.CrossRefPubMed
8.
go back to reference Bjarnason I, Smethurst P, Fenn CG, et al. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci. 1981;34:407–411.CrossRef Bjarnason I, Smethurst P, Fenn CG, et al. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci. 1981;34:407–411.CrossRef
9.
go back to reference Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol. 2008;6:1279–1282.CrossRefPubMed Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol. 2008;6:1279–1282.CrossRefPubMed
10.
go back to reference Fujimori S, Seo T, Gudis K, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc. 2009;69:1339–1346.CrossRefPubMed Fujimori S, Seo T, Gudis K, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc. 2009;69:1339–1346.CrossRefPubMed
11.
go back to reference Mizoguchi H, Ogawa Y, Kanatsu K, et al. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol. 2001;16:1112–1119.CrossRefPubMed Mizoguchi H, Ogawa Y, Kanatsu K, et al. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol. 2001;16:1112–1119.CrossRefPubMed
12.
go back to reference Kamei K, Kubo Y, Kato N, et al. Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. Dig Dis Sci. 2008;53:2657–2666.CrossRefPubMed Kamei K, Kubo Y, Kato N, et al. Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. Dig Dis Sci. 2008;53:2657–2666.CrossRefPubMed
13.
go back to reference Watanabe T, Nishio H, Tanigawa T, et al. Probiotic Lactbacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol. 2009;297:G506–G513.CrossRefPubMed Watanabe T, Nishio H, Tanigawa T, et al. Probiotic Lactbacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol. 2009;297:G506–G513.CrossRefPubMed
14.
go back to reference Satoh H, Amagase K, Takeuchi K. Mucosal protective agents prevent exacerbation of nsaid-induced small intestinal lesions caused by antisecretory drugs in rats. J Pharmacol Exp Ther. 2012;348:227–235.CrossRef Satoh H, Amagase K, Takeuchi K. Mucosal protective agents prevent exacerbation of nsaid-induced small intestinal lesions caused by antisecretory drugs in rats. J Pharmacol Exp Ther. 2012;348:227–235.CrossRef
15.
go back to reference Satoh H, Takeuchi K. Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and food constituents. Curr Med Chem. 2012;19:82–89.CrossRefPubMed Satoh H, Takeuchi K. Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and food constituents. Curr Med Chem. 2012;19:82–89.CrossRefPubMed
16.
go back to reference Satoh H, Hara T, Murakawa D, Matsuura M, Takata K. Soluble dietary fiber protects against nonsteroidal anti-inflammatory drug-induced damage to the small intestine in cats. Dig Dis Sci. 2010;55:1264–1271.CrossRefPubMed Satoh H, Hara T, Murakawa D, Matsuura M, Takata K. Soluble dietary fiber protects against nonsteroidal anti-inflammatory drug-induced damage to the small intestine in cats. Dig Dis Sci. 2010;55:1264–1271.CrossRefPubMed
17.
go back to reference Satoh H, Amagase K, Takeuchi K. The role of food for the formation and prevention of gastrointestinal lesions induced by aspirin in cats. Dig Dis Sci. 2013;58:2840–2849.CrossRefPubMed Satoh H, Amagase K, Takeuchi K. The role of food for the formation and prevention of gastrointestinal lesions induced by aspirin in cats. Dig Dis Sci. 2013;58:2840–2849.CrossRefPubMed
18.
go back to reference Satoh H, Matsumoto H, Hirakawa T, Wada N. Soluble dietary fibers can protect the small intestinal mucosa without affecting the anti-inflammatory effect of indomethacin in adjuvant-induced arthritis rats. Dig Dis Sci. 2016;61:91–98.CrossRefPubMed Satoh H, Matsumoto H, Hirakawa T, Wada N. Soluble dietary fibers can protect the small intestinal mucosa without affecting the anti-inflammatory effect of indomethacin in adjuvant-induced arthritis rats. Dig Dis Sci. 2016;61:91–98.CrossRefPubMed
19.
go back to reference Oi M, Oshida K, Sugimura S. The location of gastric ulcer. Gastroenterology. 1959;36:45–56.PubMed Oi M, Oshida K, Sugimura S. The location of gastric ulcer. Gastroenterology. 1959;36:45–56.PubMed
20.
go back to reference Satoh H, Inada I, Hirata T, Maki Y. Indomethacin produces gastric antral ulcers in the refed rat. Gastroenterology. 1981;81:719–725.PubMed Satoh H, Inada I, Hirata T, Maki Y. Indomethacin produces gastric antral ulcers in the refed rat. Gastroenterology. 1981;81:719–725.PubMed
21.
go back to reference Satoh H, Guth PH, Grossman MI. Role of food in gastrointestinal ulceration produced by indomethacin in the rat. Gastroenterology. 1982;83:210–215.PubMed Satoh H, Guth PH, Grossman MI. Role of food in gastrointestinal ulceration produced by indomethacin in the rat. Gastroenterology. 1982;83:210–215.PubMed
22.
go back to reference Satoh H, Shiotani S, Otsuka N, Hatao K, Nishimura S. Role of dietary fibres, intestinal hypermotility and leukotrienes in the pathogenesis of NSAID-induced small intestinal ulcers in cats. Gut. 2009;58:1590–1596.CrossRefPubMed Satoh H, Shiotani S, Otsuka N, Hatao K, Nishimura S. Role of dietary fibres, intestinal hypermotility and leukotrienes in the pathogenesis of NSAID-induced small intestinal ulcers in cats. Gut. 2009;58:1590–1596.CrossRefPubMed
23.
go back to reference Satoh H. Role of dietary fiber in formation and prevention of small intestinal ulcers induced by nonsteroidal anti-inflammatory drug. Curr Pharm Des. 2010;16:1209–1213.CrossRefPubMed Satoh H. Role of dietary fiber in formation and prevention of small intestinal ulcers induced by nonsteroidal anti-inflammatory drug. Curr Pharm Des. 2010;16:1209–1213.CrossRefPubMed
24.
go back to reference Takeuchi K, Satoh H. NSAID-induced small intestinal damage—roles of various pathogenic factors. Digestion. 2015;91:218–232.CrossRefPubMed Takeuchi K, Satoh H. NSAID-induced small intestinal damage—roles of various pathogenic factors. Digestion. 2015;91:218–232.CrossRefPubMed
25.
go back to reference Jeffers M, McDonald WF, Chillakuru RA, et al. A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology. 2002;123:1151–1162.CrossRefPubMed Jeffers M, McDonald WF, Chillakuru RA, et al. A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology. 2002;123:1151–1162.CrossRefPubMed
26.
go back to reference Matsuura M, Okazaki K, Nishio A, et al. Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology. 2005;128:975–986.CrossRefPubMed Matsuura M, Okazaki K, Nishio A, et al. Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology. 2005;128:975–986.CrossRefPubMed
27.
go back to reference Takeuchi K, Ueki S, Okabe S. Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats. Dig Dis Sci. 1986;31:1114–1122.CrossRefPubMed Takeuchi K, Ueki S, Okabe S. Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats. Dig Dis Sci. 1986;31:1114–1122.CrossRefPubMed
28.
go back to reference Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion. 2002;66:30–41.CrossRefPubMed Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion. 2002;66:30–41.CrossRefPubMed
29.
go back to reference Kunikata T, Tanaka A, Miyazawa T, Kato S, Takeuchi K. 16, 16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci. 2002;47:894–904.CrossRefPubMed Kunikata T, Tanaka A, Miyazawa T, Kato S, Takeuchi K. 16, 16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci. 2002;47:894–904.CrossRefPubMed
30.
go back to reference Hino S, Sonoyama K, Bito H, Kawagishi H, Aoe S, Morita T. Low-methoxyl pectin stimulates small intestinal mucin secretion irrespective of goblet cell proliferation and is characterized by jejunum Muc2 upregulation in rats. J Nutr. 2013;143:34–40.CrossRefPubMed Hino S, Sonoyama K, Bito H, Kawagishi H, Aoe S, Morita T. Low-methoxyl pectin stimulates small intestinal mucin secretion irrespective of goblet cell proliferation and is characterized by jejunum Muc2 upregulation in rats. J Nutr. 2013;143:34–40.CrossRefPubMed
31.
go back to reference Satoh H, Takeuchi K. Role of food and enterobacteria in the formation and prevention of small intestinal damage induced by NSAIDs. Front Gastrointest Res. 2012;30:52–60.CrossRef Satoh H, Takeuchi K. Role of food and enterobacteria in the formation and prevention of small intestinal damage induced by NSAIDs. Front Gastrointest Res. 2012;30:52–60.CrossRef
32.
go back to reference Licht TR, Hansen M, Bergström A, et al. Effects of apples and specific apple components on the cecal environment of conventional rats: role of apple pectin. BMC Microbiol. 2010;10:13.CrossRefPubMedPubMedCentral Licht TR, Hansen M, Bergström A, et al. Effects of apples and specific apple components on the cecal environment of conventional rats: role of apple pectin. BMC Microbiol. 2010;10:13.CrossRefPubMedPubMedCentral
33.
go back to reference Ohashi Y, Sumitani K, Tokunaga M, et al. Consumption of partially hydrolysed guar gum stimulates Bifidobacteria and butyrate-producing bacteria in the human large intestine. Benef Microbes. 2015;6:451–455.CrossRefPubMed Ohashi Y, Sumitani K, Tokunaga M, et al. Consumption of partially hydrolysed guar gum stimulates Bifidobacteria and butyrate-producing bacteria in the human large intestine. Benef Microbes. 2015;6:451–455.CrossRefPubMed
34.
35.
go back to reference Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104:S1–S63.CrossRefPubMed Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104:S1–S63.CrossRefPubMed
36.
go back to reference Jacob M, Foster R, Sigthorsson G, Simpson R, Bjarnason I. Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch Toxicol. 2007;81:291–298.CrossRefPubMed Jacob M, Foster R, Sigthorsson G, Simpson R, Bjarnason I. Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch Toxicol. 2007;81:291–298.CrossRefPubMed
37.
go back to reference Sandhu KS, el Samahi MM, Mena I, Dooley CP, Valenzuela JE. Effect of pectin on gastric emptying and gastroduodenal motility in normal subjects. Gastroenterology. 1987;92:486–492.CrossRefPubMed Sandhu KS, el Samahi MM, Mena I, Dooley CP, Valenzuela JE. Effect of pectin on gastric emptying and gastroduodenal motility in normal subjects. Gastroenterology. 1987;92:486–492.CrossRefPubMed
38.
go back to reference Schönfeld J, Evans DF, Wingate DL. Effect of viscous fiber (guar) on postprandial motor activity in human small bowel. Dig Dis Sci. 1997;42:1613–1617.CrossRefPubMed Schönfeld J, Evans DF, Wingate DL. Effect of viscous fiber (guar) on postprandial motor activity in human small bowel. Dig Dis Sci. 1997;42:1613–1617.CrossRefPubMed
39.
go back to reference Zhu Y, Hsu WH, Hollis JH. The impact of food viscosity on eating rate, subjective appetite, glycemic response and gastric emptying rate. PLoS One. 2013;8:e67482.CrossRefPubMedPubMedCentral Zhu Y, Hsu WH, Hollis JH. The impact of food viscosity on eating rate, subjective appetite, glycemic response and gastric emptying rate. PLoS One. 2013;8:e67482.CrossRefPubMedPubMedCentral
40.
go back to reference Ehrlein HJ, Pröve J. Effect of viscosity of test meals on gastric emptying in dogs. Q J Exp Physiol. 1982;67:419–425.CrossRefPubMed Ehrlein HJ, Pröve J. Effect of viscosity of test meals on gastric emptying in dogs. Q J Exp Physiol. 1982;67:419–425.CrossRefPubMed
Metadata
Title
Soluble Dietary Fiber Can Protect the Gastrointestinal Mucosa Against Nonsteroidal Anti-Inflammatory Drugs in Mice
Authors
Hiroshi Satoh
Tetsuro Urushidani
Publication date
01-07-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4086-5

Other articles of this Issue 7/2016

Digestive Diseases and Sciences 7/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine